|Table of Contents|

Research progress on the mechanism of SLFN11 involvement in DNA damage response

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
149-157
Research Field:
Publishing date:

Info

Title:
Research progress on the mechanism of SLFN11 involvement in DNA damage response
Author(s):
HE Yijia1; YANG Boxuan1; LONG Yuhou1; LOU Ming1; GOU Xingchun2; ZHANG Zhenhao2; GAO Xingchun3; LAO Kejing2
1.School of Stomatology,Xi'an Medical University,Shaanxi Xi'an 710021,China;2.Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medical Science,Xi'an Medical University,Shaanxi Xi'an 710021,China;3.Department of lmmunology,School of Basic Medical Sciences,Xi'an Medical University,Shaanxi Xi'an 710021,China.
Keywords:
SLFN11; therapeutic target; drug resistance; DDR; cancers
PACS:
R730
DOI:
10.3969/j.issn.1672-4992.2025.01.024
Abstract:
Drug resistance has become an urgent problem to be solved in cancer chemotherapy.DNA-damage agents (DDA) are important drugs using in cancer chemotherapy,but cancer cells can repair the damage through DNA-damage response (DDR),thereby reducing the killing effect of chemotherapy drugs.Therefore,elucidating the mechanism of DNA-damage response is of great significance for increasing the sensitivity of chemotherapy drugs and reducing the dosage of chemotherapy drugs.Schlafen 11 (SLFN11) is a DNA/RNA helicase that can sensitize the killing effect of DNA-damage agents on cancer cells.Previous studies have shown that the expression level of SLFN11 in various cancers is significantly positively correlated with the sensitivity of cancer cell DNA-damage agents.Therefore,SLFN11 can be used as a predictive biomarker and target of the therapeutic effect of chemotherapy drugs.This review summarises the structure of SLFN11,the mechanism of action involved in DDR,and the research progress in its application in different cancers,providing new strategies for precise anti-cancer therapy and innovative drug development in clinical treatment.

References:

［1］ GROELLY FJ,FAWKES M,DAGG RA,et al.Targeting DNA damage response pathways in cancer［J］.Nature Reviews Cancer,2023,23(2):78-94.
[2] JITOBAOM K,SIRIHONGTHONG T,BOONARKART C,et al.Human Schlafen 11 inhibits influenza A virus production［J］.Virus Research,2023,334:199162.
[3] JO U,POMMIER Y.Structural,molecular,and functional insights into Schlafen proteins［J］.Experimental & Molecular Medicine,2022,54(6):730-738.
[4] METZNER FJ,WENZL SJ,KUGLER M,et al.Mechanistic understanding of human SLFN11［J］.Nature Communications,2022,13(1):5464.
[5] WATANABE K,SEKI N.Biology and development of DNA-targeted drugs,focusing on synthetic lethality,dna repair,and epigenetic modifications for cancer:a review［J］.International Journal of Molecular Sciences,2024,25(2):752.
[6] MURAI J,TANG SW,LEO E,et al.SLFN11 blocks stressed replication forks independently of ATR［J］.Molecular Cell,2018,69(3):371-384.
[7] RAYNAUD CM,AHMED EI,JABEEN A,et al.Modulation of SLFN11 induces changes in DNA damage response in breast cancer［J］.Cancer Cell International,2023,23(1):291.
[8] BRADBURY A,HALL S,CURTIN N,et al.Targeting ATR as cancer therapy:A new era for synthetic lethality and synergistic combinations［J］.Pharmacology & Therapeutics,2020,207:107450.
[9] LI M,KAO E,MALONE D,et al.DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs［J］.Nature Structural & Molecular Biology,2018,25(11):1047-1058.
[10] FUJIWARA K,MAEKAWA M,IIMORI Y,et al.The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13［J］.iScience,2023,26(12):108529-180573.
[11] TANG SW,THOMAS A,MURAI J,et al.Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors［J］.Clinical Cancer Research,2018,24(8):1944-1953.
[12] LUAN J,GAO X,HU F,et al.SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)［J］.Journal of Drug Targeting,2020,28(1):33-40.
[13] SHEE K,WELLS JD,JIANG A,et al.Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy［J］.PLoS One,2019,14(11):e0224267.
[14] 韩欣晟,李坤,赵英男,等.髓母细胞瘤靶向治疗的研究进展［J］.医学综述,2022,28(11)：2128-2133. HAN XS,LI K,ZHAO YN,et al.Research progress in targeted treatment of medulloblastoma［J］.Medical Recapitulate,2022,28(11)：2128-2133.
[15] SHENG H,LI H,ZENG H,et al.Heterogeneity and tumoral origin of medulloblastoma in the single-cell era［J］.Oncogene,2024,43(12):839-850.
[16] NAKATA S,MURAI J,OKADA M,et al.Epigenetic upregulation of Schlafen11 renders WNT- and SHH-activated medulloblastomas sensitive to cisplatin［J］.Neuro-oncology,2023,25(5):899-912.
[17] 摆俊博,陶宁,邱瑞莹,等.去势抵抗性前列腺癌的危险因素及神经侵犯对疾病进展的评估价值［J］.现代泌尿外科杂志,2022,27(3):210-217. BAI JB,TAO N,QIU RY,et al.Risk factors of castration-resistant prostate cancer and value of perineurainvasion in evaluating disease progression［J］.Journal of Modern Urology,2022,27(3):210-217.
[18] CONTEDUCA V,KU SY,PUCA L,et al.SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy［J］.Molecular Cancer Therapeutics,2020,19(5):1157-1164.
[19] KAUR S,SCHWARTZ AL,JORDAN DG,et al.Identification of Schlafen-11 as a target of CD47 signaling that regulates sensitivity to ionizing radiation and topoisomerase inhibitors［J］.Frontiers in Oncology,2019,9:994.
[20] 张雪,董晓平,管雅喆,等.女性乳腺癌流行病学趋势及危险因素研究进展［J］.肿瘤防治研究,2021,48(1):6. ZHANG X,DONG XP,GUAN YZ,et al.Research progress on epidemiological trend and risk factors of female breast cancer［J］.Cancer Research on Prevention and Treatment,2021,48(1):6.
[21] COUSSY F,EL-BOTTY R,CHTEAU-JOUBERT S,et al.BRCAness,SLFN11,and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers［J］.Science Translational Medicine,2020,12(531):eaax2625.
[22] 姜凤丽,吴天一,吴凡.高级别浆液性卵巢癌关键驱动基因的研究进展［J］.医学综述,2021,27(13):2583-2588. JIANG FL,WU TY,WU F.Research progress of key driver genes in high-grade serous ovarian carcinoma［J］.Medical Recapitulate,2021,27(13):2583-2588.
[23] TSERPELI V,STERGIOPOULOU D,LONDRA D,et al.Prognostic significance of SLFN11 methylation in plasma cell-free DNA in advanced high-grade serous ovarian cancer［J］.Cancers,2021,14(1):1-15.
[24] WINKLER C,KING M,BERTHE J,et al.SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer［J］.JCI Insight,2021,6(18):e146098.
[25] CHRISTOFYLLAKIS K,MONTEIRO AR,CETIN O,et al.Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults:A Young International Society of Geriatric Oncology report［J］.Journal of Geriatric Oncology,2022,13(8):1071-1083.
[26] KRUSHKAL J,SILVERS T,REINHOLD WC,et al.Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets［J］.Clinical Epigenetics,2020,12(1):93.
[27] KUNDU K,CARDNELL RJ,ZHANG B,et al.SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer［J］.Translational Lung Cancer Research,2021,10(11):4095-4105.
[28] LOK BH,GARDNER EE,SCHNEEBERGER VE,et al.PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer［J］.Clinical Cancer Research,2017,23(2):523-535.
[29] YIN YP,MA LY,CAO GZ,et al.FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11［J］.Acta Pharmacologica Sinica,2022,43(8):2119-2127.
[30] TAYOUN T,FAUGEROUX V,OULHEN M,et al.Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants［J］.JCI Insight,2022,7(11):e155804.
[31] 陈晓晗,陆静钰,陆海军.头颈部鳞状细胞癌靶向治疗进展［J］.现代肿瘤医学,2021,29(09):1632-1635. CHEN XH,LU JY,LU HJ.Advances in targeted therapy for head and neck squamous cell carcinoma［J］.Modern Oncology,2021,29(09):1632-1635.
[32] LEE TW,WONG WW,DICKSON BD,et al.Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia［J］.International Journal of Radiation Biology,2019,95(12):1597-1612.
[33] 刘宇英,魏君丽,江柔,等.食管癌的流行病学及筛查研究进展［J］.中华疾病控制杂志,2022,26(07)：839-844. LIU YY,WEI JL,JIANG R,et al.Research progress on the epidemiology and screening of esophageal cancer［J］.Chinese Journal of Disease Control and Prevention,2022,26(07):839-844.
[34] KAGAMI T,YAMADE M,SUZUKI T,et al.The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy［J］.BMC Cancer,2020,20(1):1123.
[35] 李娟,刘家仁.胃癌免疫治疗的研究现状及进展［J］.实用肿瘤学杂志,2023,37(04):372-376. LI J,LIU JR.The current research status and progress of immunotherapy for gastric cancer［J］.Practical Oncology Journal,2023,37(04):372-376.
[36] TAKASHIMA T,TANIYAMA D,SAKAMOTO N,et al.Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers［J］.British Journal of Cancer,2021,125(1):65-77.
[37] PENG Y,WANG L,WU L,et al.Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin［J］.Journal of Cancer,2019,10(24):6124-6134.
[38] GONG H,XUE B.Targeted therapy for EWS-FLI1 in Ewing sarcoma［J］.Cancer(Basel),2023,15(16):4035-4056.
[39] IWASAKI J,KOMORI T,NAKAGAWA F,et al.Schlafen11 expression is associated with the antitumor activity of trabectedin in human sarcoma cell lines［J］.Anticancer Research,2019,39(7):3553-3563.
[40] WATERS T,GOSS KL,KOPPENHAFER SL,et al.Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication［J］.BMC Cancer,2020,20(1):1171.
[41] ZHAO M,DIPERI TP,RASO MG,et al.Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan［J］.npj Breast Cancer,2023,9(1):66.
[42] MAO S,CHAERKADY R,YU W,et al.Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR.［J］.American Association for Cancer Research (AACR),2021,20(3):541-552.
[43] TANG SW,THOMAS A,MURAI J,et al.Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors［J］.Clinical Cancer Research,2018,15,24(8):1944-1953.

Memo

Memo:
陕西省自然科学基础研究计划项目（编号：2023-JC-QN-0137）；陕西省青年科技新星项目(编号：2023KJXX-066)；陕西省科技厅一般项目-社会发展领域（编号：2022SF-020）；陕西省科技创新团队项目（编号：2021TD-48）；陕西省教育厅青年创新团队项目(编号：23JP152）；陕西省大学生创新创业训练计划项目(编号：S202211840053)；西安医学院大学生创新训练计划项目（编号：121522053）
Last Update: 1900-01-01